Following the landmark success of CPHI & PMEC China in June 2026, which welcomed an unprecedented gathering of industry professionals and fostered pivotal connections across the pharmaceutical supply ...

Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.

Innovative Pharmaceutical Biotech (HK:0399) has released an update. Innovative Pharmaceutical Biotech Limited has entered into a Memorandum of Understanding to potentially acquire a majority stake in ...

Biotech remains one of the market's more out-of-favor sectors despite improving industry fundamentals. Here are three stocks trading near multiyear lows.

The "Co-promotion and Co-marketing in Pharmaceuticals and Biotechnology 2016-2026" has been added to ResearchAndMarkets.com's offering.The Co-promotion and Co-marketing Deals in Pharmaceuticals and ...

DUBLIN--(BUSINESS WIRE)--The "Manufacturing and Supply Deals in Pharmaceuticals and Biotechnology 2020-2025" has been added to ResearchAndMarkets.com's offering. This report contains a comprehensive ...

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with ...

X4 Pharmaceuticals is rated BUY, driven by a funded Phase 3 trial, current product pipeline, and a strong cash position extending into 2028. XFOR's primary value lies in its 4WARD Phase 3 trial in ...

It's been a volatile year for the company, but don't let that scare you away.

Interview with the Chairman and CEO: MAIA Biotechnology Inc. (NYSEAMERICAN:MAIA) Vlad Vitoc Interview with the Chairman and CEO: Mira Pharmaceuticals, Inc. (NASDAQ:MIRA) and Telomir Pharmaceuticals, ...

As predicted by many analysts, economists, and investors, the sweeping tariffs announced by the Trump administration on Wednesday decimated the stock market on Thursday. It had one of its worst ...

PJP delivers lower volatility and higher income with concentrated pharma exposure, while XBI offers broader biotech growth at ...